Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.

Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S.

Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 10.1080/17512433.2019.1623669. Epub 2019 Jun 13. Review.

PMID:
31159608
2.

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study.

Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, La Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL, Romeo A.

Cancers (Basel). 2019 May 13;11(5). pii: E663. doi: 10.3390/cancers11050663.

3.

SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.

Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, Ochudlo S, Banach M, Pagan F, Flatau-Baqué B, Csikós J, Cairney CJ, Blitzer A.

Neurology. 2019 Apr 23;92(17):e1982-e1991. doi: 10.1212/WNL.0000000000007368. Epub 2019 Mar 27.

4.

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.

Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Arellano J, Howard HH, Peyton M, Matar S, Liu X, Fowler AJ, Schwartz SL, Ahn J, Moussa C.

Pharmacol Res Perspect. 2019 Mar 12;7(2):e00470. doi: 10.1002/prp2.470. eCollection 2019 Apr.

5.

Health equity-oriented approaches to inform responses to opioid overdoses: a scoping review protocol.

MacKinnon K, Pauly B, Shahram S, Wallace B, Urbanoski K, Gordon C, Raworth R, MacDonald M, Marcellus L, Sawchuck D, Pagan F, Strosher H, Inglis D, Macevicius C, Strayed N.

JBI Database System Rev Implement Rep. 2019 May;17(5):640-653. doi: 10.11124/JBISRIR-2017-003933.

PMID:
30889075
6.

Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.

Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B.

Alzheimers Res Ther. 2019 Mar 13;11(1):23. doi: 10.1186/s13195-019-0476-1.

7.

The implementation of overdose prevention sites as a novel and nimble response during an illegal drug overdose public health emergency.

Wallace B, Pagan F, Pauly BB.

Int J Drug Policy. 2019 Apr;66:64-72. doi: 10.1016/j.drugpo.2019.01.017. Epub 2019 Jan 29.

8.

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi: 10.2147/CMAR.S181570. eCollection 2018.

9.

Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.

Keys Lawler AC, Torres-Yaghi Y, Amjad F, Moussa C, Pagan F.

Neurol Clin Pract. 2018 Jun;8(3):175. doi: 10.1212/CPJ.0000000000000467. No abstract available.

10.

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.

Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M.

Tumori. 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704. Epub 2018 May 9.

PMID:
29739298
11.

Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy.

Casadei Gardini A, Passardi A, Fornaro L, Rosetti P, Valgiusti M, Ruscelli S, Monti M, Casadei C, Pagan F, Frassineti GL.

Crit Rev Oncol Hematol. 2018 Mar;123:52-56. doi: 10.1016/j.critrevonc.2018.01.007. Epub 2018 Feb 2. Review.

PMID:
29482779
12.

The diagnosis and natural history of Huntington disease.

Pagan F, Torres-Yaghi Y, Altshuler M.

Handb Clin Neurol. 2017;144:63-67. doi: 10.1016/B978-0-12-801893-4.00005-5. Review.

PMID:
28947126
13.

Erratum to: Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases.

Purks JL, Wilhelm EE, Shoulson I, Creveling J, Dorsey ER, Irony T, LoCastro TM, Pagan F, Ravina B, Simuni T, Sterling M, Tariot P, Anderson KE.

Patient. 2017 Oct;10(5):667-668. doi: 10.1007/s40271-017-0271-7. No abstract available.

PMID:
28766071
14.

Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases.

Purks JL, Wilhelm EE, Shoulson I, Creveling J, Dorsey ER, Irony T, LoCastro TM, Pagan F, Ravina B, Simuni T, Sterling M, Tariot P, Anderson KE.

Patient. 2017 Oct;10(5):541-544. doi: 10.1007/s40271-017-0257-5. No abstract available. Erratum in: Patient. 2017 Oct;10 (5):667-668.

15.

The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.

Hermanowicz N, Alva G, Pagan F, Espay AJ, Patel A, Madrid KC, Kremens D, Kenney J, Arquette S, Tereso G, Lopes M, Farnum C.

J Manag Care Spec Pharm. 2017 Jun;23(6-b Suppl):S2-S8. doi: 10.18553/jmcp.2017.23.6-b.s2. Review.

16.

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE.

Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316. Review.

17.

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.

Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F.

Mov Disord Clin Pract. 2017 Jan-Feb;4(1):78-83. doi: 10.1002/mdc3.12350. Epub 2016 May 25.

18.

A Screening Tool to Identify Spasticity in Need of Treatment.

Zorowitz RD, Wein TH, Dunning K, Deltombe T, Olver JH, Davé SJ, Dimyan MA, Kelemen J, Pagan FL, Evans CJ, Gillard PJ, Kissela BM.

Am J Phys Med Rehabil. 2017 May;96(5):315-320. doi: 10.1097/PHM.0000000000000605.

19.

Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.

Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Falconer RA, Ahn J, Li Z, Moussa C.

J Parkinsons Dis. 2016 Jul 11;6(3):503-17. doi: 10.3233/JPD-160867.

20.

Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.

Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A; MODERATO Investigators.

Mov Disord. 2016 May;31(5):709-14. doi: 10.1002/mds.26617. Epub 2016 Mar 31.

PMID:
27030249
21.

Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A.

Mills RR, Pagan FL.

Patient Prefer Adherence. 2015 Jun 2;9:725-31. doi: 10.2147/PPA.S75459. eCollection 2015. Review.

22.

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy.

Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE.

J Clin Cell Immunol. 2014 Sep 30;5:259.

23.

An update on the use of botulinum toxin therapy in Parkinson's disease.

Mills R, Bahroo L, Pagan F.

Curr Neurol Neurosci Rep. 2015 Jan;15(1):511. doi: 10.1007/s11910-014-0511-3. Review.

PMID:
25407133
24.

Peri-Implant Response and Microflora in Organ Transplant Patients 1 Year after Prosthetic Loading: A Prospective Controlled Study.

Montebugnoli L, Venturi M, Cervellati F, Servidio D, Vocale C, Pagan F, Landini MP, Magnani G, Sambri V.

Clin Implant Dent Relat Res. 2015 Oct;17(5):972-82. doi: 10.1111/cid.12207. Epub 2014 Feb 24.

PMID:
24612063
25.

Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia.

Fernandez HH, Pagan F, Danisi F, Greeley D, Jankovic J, Verma A, Sethi K, Pappert EJ; XCiDaBLE Study Group.

Tremor Other Hyperkinet Mov (N Y). 2013 May 17;3. pii: tre-03-139-2924-1. doi: 10.7916/D8CF9NVD. Print 2013.

26.

Improving outcomes through early diagnosis of Parkinson's disease.

Pagan FL.

Am J Manag Care. 2012 Sep;18(7 Suppl):S176-82. Review.

PMID:
23039866
27.

A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.

Pagan FL, Harrison A.

Parkinsonism Relat Disord. 2012 Jun;18(5):441-5. doi: 10.1016/j.parkreldis.2012.02.008. Epub 2012 Mar 9. Review.

PMID:
22405829
28.

The national DBS brain tissue network pilot study: need for more tissue and more standardization.

Vedam-Mai V, Krock N, Ullman M, Foote KD, Shain W, Smith K, Yachnis AT, Steindler D, Reynolds B, Merritt S, Pagan F, Marjama-Lyons J, Hogarth P, Resnick AS, Zeilman P, Okun MS.

Cell Tissue Bank. 2011 Aug;12(3):219-31. doi: 10.1007/s10561-010-9189-1. Epub 2010 Jun 30.

PMID:
20589432
29.

CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease.

Shimoji M, Pagan F, Healton EB, Mocchetti I.

Neurotox Res. 2009 Oct;16(3):318-28. doi: 10.1007/s12640-009-9076-3. Epub 2009 Jun 24.

PMID:
19551455
30.

Safety of MRI in patients with implanted deep brain stimulation devices.

Tagliati M, Jankovic J, Pagan F, Susatia F, Isaias IU, Okun MS; National Parkinson Foundation DBS Working Group.

Neuroimage. 2009 Aug;47 Suppl 2:T53-7. doi: 10.1016/j.neuroimage.2009.04.044. Epub 2009 Apr 17.

PMID:
19376247
31.

Involvement of insula and cingulate cortices in control and suppression of natural urges.

Lerner A, Bagic A, Hanakawa T, Boudreau EA, Pagan F, Mari Z, Bara-Jimenez W, Aksu M, Sato S, Murphy DL, Hallett M.

Cereb Cortex. 2009 Jan;19(1):218-23. doi: 10.1093/cercor/bhn074. Epub 2008 May 9.

32.

Monitoring brain tissue oxygen tension in brain-injured patients reveals hypoxic episodes in normal-appearing and in peri-focal tissue.

Longhi L, Pagan F, Valeriani V, Magnoni S, Zanier ER, Conte V, Branca V, Stocchetti N.

Intensive Care Med. 2007 Dec;33(12):2136-42. Epub 2007 Sep 1.

PMID:
17846748
33.

Neuroimaging of neuronal circuits involved in tic generation in patients with Tourette syndrome.

Lerner A, Bagic A, Boudreau EA, Hanakawa T, Pagan F, Mari Z, Bara-Jimenez W, Aksu M, Garraux G, Simmons JM, Sato S, Murphy DL, Hallett M.

Neurology. 2007 Jun 5;68(23):1979-87.

PMID:
17548547
34.

Small de novo duplication in the repeat region of the TATA-box-binding protein gene manifest with a phenotype similar to variant Creutzfeldt-Jakob disease.

Shatunov A, Fridman EA, Pagan FI, Leib J, Singleton A, Hallett M, Goldfarb LG.

Clin Genet. 2004 Dec;66(6):496-501.

PMID:
15521976
35.

Inaccurate early assessment of neurological severity in head injury.

Stocchetti N, Pagan F, Calappi E, Canavesi K, Beretta L, Citerio G, Cormio M, Colombo A.

J Neurotrauma. 2004 Sep;21(9):1131-40.

PMID:
15453984
36.

[How to quantify the severity of brain injury during intensive care after adult head trauma].

Stocchetti N, Canavesi K, Longhi L, Magnoni S, Protti A, Pagan F, Colombo A.

Minerva Anestesiol. 2003 Apr;69(4):232-6. Review. Italian.

37.

Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy.

Pagan FL, Butman JA, Dambrosia JM, Hallett M.

Neurology. 2003 Apr 22;60(8):1344-7.

PMID:
12707440
38.

Primary lateral sclerosis: A heterogeneous disorder composed of different subtypes?

Zhai P, Pagan F, Statland J, Butman JA, Floeter MK.

Neurology. 2003 Apr 22;60(8):1258-65.

PMID:
12707427
39.

A new drug for an old condition?

Pagan FL, Restrepo L, Balish M, Patwa HS, Houff S.

Headache. 2002 Jul-Aug;42(7):695-6. No abstract available.

PMID:
12482228
40.

Review of 17 cases of pneumonia caused by Streptococcus pyogenes.

Barnham M, Weightman N, Anderson A, Pagan F, Chapman S.

Eur J Clin Microbiol Infect Dis. 1999 Jul;18(7):506-9.

PMID:
10482030
41.

Protection from oxidation enhances the survival of cultured mesencephalic neurons.

Colton CA, Pagan F, Snell J, Colton JS, Cummins A, Gilbert DL.

Exp Neurol. 1995 Mar;132(1):54-61.

PMID:
7720826
42.

What cord care--if any?

Verber IG, Pagan FS.

Arch Dis Child. 1993 May;68(5 Spec No):594-6.

43.

Antibiotics for gram-positive organisms.

Pagan FS.

Br J Hosp Med. 1981 Jan;25(1):24-7.

PMID:
7470716
44.

Effect of cimetidine on absorption of oral benzylpenicillin.

Fairfax AJ, Adam J, Pagan FS.

Br Med J. 1978 Apr 1;1(6116):820. No abstract available.

45.

Sensitivity of Bacteroides species to clindamycin.

Pagan FS.

J Antimicrob Chemother. 1978 Jan;4(1):91. No abstract available.

PMID:
624695
46.

Experimental selection of influenza virus mutants (subtype A0 and A1): haemagglutinin.

Cinco M, Rottini G, Pagan F.

Zentralbl Bakteriol Orig A. 1973 Oct;224(4):413-21. No abstract available.

PMID:
4150106

Supplemental Content

Support Center